Company intelligence / Profile preview
XYRA LLC
Los Altos, California, United States
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Phase 2 clinical trials showed that budiodarone suppresses AF burden, eliminates long episodes, and improves symptoms in a dose-dependent fashion while maintaining a favorable safety profile. The company has reached agreement with the FDA at End of Phase 2 meetings on key studies for approval and labeling of budiodarone for long-term management of symptomatic non-permanent atrial fibrillation.[2][4][5]
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on XYRA LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XYRA LLC.